|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Staging systems of hepatocellular carcinoma:A review of literature显示文摘Hepatocellular carcinoma(HCC)is a major health problem with a high incidence and mortality all over the world.Natural history of HCC is severe and extremely variable,and prognostic factors influencing outcomes are incompletely defined.Over time,many staging and scoring systems have been proposed for the classification and prognosis of patients with HCC.Currently,the non-ideal predictive performance of existing prognostic systems is secondary to their inherent limitations,as well as to a non-universal reproducibility and transportability of the results in different populations.New serological and histological markers are still under evaluation with promising results,but they require further evaluation and external validation.The aim of this review is to highlight the main tools for assessing the prognosis of HCC and the main concerns,pitfalls and warnings regarding its staging systems currently in use. | Marcello Maida Emanuele Orlando Calogero Cammà Giuseppe Cabibbo | 2014 | World Journal of Gastroenterology2014，20，15： | 11 |
| 2 | untreatable hepatocellular 癌的自然历史: 回顾的队研究显示文摘 AIM:To investigate the clinical course of untreatable hepatocellular carcinoma(HCC) identified at any stage and to identify factors associated with mortality.METHODS:From January 1999 to December 2010,320 out of 825 consecutive patients with a diagnosis of HCC and not appropriate for curative or palliative treatments were followed and managed with supportive therapy.Cirrhosis was diagnosed by histological or clinical features and liver function was evaluated according to Child-Pugh score.The diagnosis of HCC was performed by Ultra-Sound guided biopsy or by multiphasic contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging.Data were collected for each patient including all clinical,laboratory and imaging variables necessary for the outcome prediction staging systems considered.HCC staging was performed according Barcelona Clinic Liver Cancer(BCLC) and Cancer of the Liver Italian Program scores.Follow-up time was defined as the number of months from the diagnosis of HCC to death.Prognostic baseline variables were analyzed by multivariate Cox analysis to identify the independent predictors of survival.RESULTS:Seventy-five per cent of patients had hepatitis C.Ascites was present in 169 patients(53%),while hepatic encephalopathy was present in 49 patients(15%).The Child-Pugh score was class A in 105 patients(33%),class B in 142 patients(44%),and class C in 73 patients(23%).One hundred patients(31%) had macroscopic vascular invasion and/or extrahepatic spread of the tumor.A single lesion > 10 cm was observed in 34 patients(11%),while multinodular HCC was present in 189 patients(59%).Thirty nine patients(12%) were BCLC early(A) stage,55(17%) were BCLC intermediate(B) stage,124(39%) were BCLC advanced(C) stage,and 102(32%) were endstage BCLC(D).At the time of this analysis(July 2011),28(9%) patients were still alive.Six(2%) patients who were lost during follow-up were censored at the last visit.The overall median survival was 6.8 mo,and the 1-year survival was 32%.The 1-year survival according to BCLC classes was 100%,79%,12% and 0%,for BCLC A,B,C and D,respectively.There was a significant difference in survival between each BCLC class.The median survival of patients of BCLC stages A,B,C and D was 33,17.4,6.9,and 1.8 mo,respectively(P < 0.05 for comparison between stages).The median survival of Child-Pugh A,B and C classes were 9.8 mo(range 6.4-13),6.1(range 4.9-7.3),and 3.7(range 1.5-6),respectively(P < 0.05 for comparison between stages).By univariate analysis,the variables significantly associated to an increased liklihood of mortality were Eastern Cooperative Oncology Group performance status(PS),presence of ascites,low level of albumin,elevated level of bilirubin,international normalized ratio(INR) and Log-[(α fetoprotein(AFP)].At multivariate analysis,mortality was independently predicted by bad PS(P < 0.0001),high INR values(P = 0.0001) and elevated Log-(AFP) levels(P = 0.009).CONCLUSION:This study confirms the heterogeneous behavior of untreated HCC.BCLC staging remains an important prognostic guide and may be important in decision-making for palliative treatment. | Giuseppe Cabibbo Marcello Maida Chiara Genco Pietro Parisi Marco Peralta Michela Antonucci Giuseppe Brancatelli Calogero Cammà Antonio Craxì Vito Di Marco | 2012 | World Journal of Hepatology2012，4，9： | 11 |
| 3 | Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure显示文摘Hepatocellular carcinoma(HCC) is the main cause of death in patients with cirrhosis, with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Over time several randomized phase Ⅲ trials have been performed testing sunitinib, brivanib, linifanib and other molecules in head-tohead comparison with Sorafenib as first-line treatment for advanced-stage HCC, but none of these has so far been registered in this setting. Moreover, another feared vacuum arises from the absence of molecules registered as second-line therapy for patients who have failed Sorafenib, representing an urgent unmet medical need. To date all molecules tested as second-line therapies for advanced hepatocellular carcinoma, failed to demonstrate an increased survival compared to placebo. What are the possible reasons for the failure? What we should expect in the near future? | Marcello Maida Massimo Iavarone Maurizio Raineri Calogero Cammà Giuseppe Cabibbo | 2015 | World Journal of Hepatology2015，7，17： | 7 |
| 4 | Hyperferritinemia is a risk factor for steatosis in chronic liver disease显示文摘AIM: To investigate the relationship between ferritin and steatosis in patients with chronically abnormal liver function tests (LFTs) and high ferritin level. METHODS: One hundred and twenty-four consecutive patients with hyperferritinemia (male > 300 ng/mL, female > 200 ng/mL) were evaluated; clinical, biochemical and serological data, iron status parameters, HFE gene mutations and homeostasis model assessment score were obtained. Steatosis was graded by ultrasound as absent or present. Histology was available in 53 patients only. RESULTS: Mean level of ferritin was 881 ± 77 ng/mL in men and 549 ± 82 ng/mL in women. The diagnosis was chronic hepatitis C in 53 (42.7%), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in 57 (45.9%), and cryptogenic liver damage in 14 (11.3%). None was diagnosed as hereditary hemochromatosis (HH). Hepatic siderosis on liver biopsy was present in 17 of 54 (32%) patients; grade 1 in eight and grade 2 in nine. Overall, 92 patients (74.2%) had steatosis. By logistic regression, ferritin and γ-glutamyltransferase were independent predictors of steatosis. Ferritin levels were signifi cantly related to low platelet count, steatosis and hepatitis C virus infection. CONCLUSION: In a non-obese cohort of non-alcoholic patients with chronically abnormal LFTs without HH, high serum ferritin level is a risk factor for steatosis. | Anna Licata Maria Elena Nebbia Giuseppe Cabibbo Giovanna Lo Iacono Francesco Barbaria Virna Brucato Nicola Alessi Salvatore Porrovecchio Vito Di Marco Antonio Craxì Calogero Cammà | 2009 | World Journal of Gastroenterology2009，15，17： | 6 |
| 5 | Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis显示文摘 | Erica Villa Calogero Cammà Marco Marietta Monica Luongo Rosina Critelli Stefano Colopi Cristina Tata Ramona Zecchini Stefano Gitto Salvatore Petta Barbara Lei Veronica Bernabucci Ranka Vukotic Nicola De Maria Filippo Schepis Aimilia Karampatou Cristian Ca | 2012 | Gastroenterology2012，，5： | 5 |
| 6 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach显示文摘 | Calogero Cammà Marco Giunta Pietro Andreone Antonio Crax?? | 2001 | Journal of Hepatology2001，，4： | 2 |
| 7 | 鱼油对植入埋藏式心脏复律除颤器患者室性快速性心律失常及死亡的影响:ω-3脂肪酸与室性心律失常(SOFA)随机化研究 | Brouwer I.A. Zock P.L. Camm A.J. 任付先 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，0，11： | 2 |
| 8 | IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease显示文摘 | Salvatore Petta Stefania Grimaudo Calogero Cammà Daniela Cabibi Vito Di Marco Giusalba Licata Rosaria Maria Pipitone Antonio Craxì | 2012 | Journal of Hepatology2012，，6： | 2 |
| 9 | Development and validation of fast Real-Time PCR assays for species identification in raw and cooked meat mixtures显示文摘 | Cesare Cammà Marco Di Domenico Federica Monaco | 2011 | Food Control2011，，2： | 2 |
| 10 | PNPLA 3 rs738409 I748M is associated with steatohepatitis in 434 non‐obese subjects with hepatitis C显示文摘 | S. Petta E. Vanni E. Bugianesi C. Rosso D. Cabibi C. Cammà V. Di Marco M. Eslam S. Grimaudo F. S. Macaluso D. McLeod R. M. Pipitone M. L. Abate A. Smedile J. George A. Craxì | 2015 | Aliment Pharmacol Ther2015，，10： | 2 |
| 11 | Field‐practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy显示文摘 | Massimo Iavarone Giuseppe Cabibbo Fabio Piscaglia Claudio Zavaglia Antonio Grieco Erica Villa Calogero Cammà Massimo Colombo | 2011 | Hepatology2011，，6： | 2 |
| 12 | Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance显示文摘 | Irene Savelieva Antonios Kourliouros John Camm | 2010 | Naunyn - Schmiedeberg’s Archives of Pharmacology2010，，3： | 2 |
| 13 | Drug induced QT prolongation and torsades de pointes显示文摘 | Yap YG Camm AJ | 2003 | Heart2003，89，： | 1 |
| 14 | Single-chamber versus dualchamber pacing for high-grade atrioventricular block 显示文摘 | Toff WD Camm A J Skehan JD | 2005 | N Engl J Med2005，353，： | 1 |
| 15 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death显示文摘 | Zipes D P Camm A J Borggrefe M | 2006 | J Am Coll Cardiol2006，48，5： | 1 |
| 16 | ACC/AHA/ESC 2006Guidelines for management of pa-tients with ventricular arrhythmias and the prevention of sudden cardiac death显示文摘 | ZIPES D CAMM A J BORGGREFE M | 2006 | Circulation2006，114，： | 1 |
| 17 | Sinus tachyarrhythmias and the specific bradycardic agents:A marriage made in heaven显示文摘 | Yusuf S Camm AJ | 2003 | J Cardiovasc Pharmacol Ther2003，8，： | 1 |
| 18 | Task force of the european society of cardiology and North American society of pacing and eleetrophysiology, Heart rate varicbility standards of measurement, physiological interpretation and clinical use 显示文摘 | Camm AI Malik M Bigger JE et al | 1996 | Circulation1996，93，： | 1 |
| 19 | Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial 显示文摘 | Camm AJ Toil E Torp-Pedersen C | 2012 | Europace2012，14，6： | 1 |
| 20 | Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fi- brillation of the European Society of Cardiology (ESC) 显示文摘 | Camm AJ Kirehhof P Lip GY | 2010 | Europace2010，12，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员